View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Eli Lilly and Company: Update to credit analysis following outlook cha...

Our credit view of this issuer reflects its growth portfolio in oncology, neuroscience and immunology, offset by its revenue concentration in diabetes / metabolic conditions.

Moody's Ratings affirms Eli Lilly's Aa3 rating; revises outlook to pos...

Moody's Ratings (Moody's) affirmed the ratings of Eli Lilly and Company ("Lilly") including the Aa3 senior unsecured notes ratings and long-term issuer rating, the (P)Aa3 senior unsecured shelf and medium term note program ratings, and the Prime-1 short-term commercial paper rating. At the same time...

Moody's Ratings assigns Baa2 to Campbell's proposed notes

Moody's Ratings (Moody's) today assigned Baa2 ratings to the senior unsecured notes being offered in a 5 year tranche by The Campbell's Company ("Campbell"). All other ratings of the company remain unchanged including the Baa2 senior unsecured and Prime-2 commercial paper ratings. The ratings outloo...

Vikash Harlalka
  • Vikash Harlalka

The future of broadband - Optimum Fiber has higher cNPS than Optimum C...

Optimum’s cNPS for their fiber product is higher than their Cable product but the gap has decreased in recent months. Fiber cNPS has decreased and Cable cNPS has increased slightly. As the size of Optimum’s Fiber customer base increases, the overall cNPS should inch higher. More importantly, Fiber scores are higher than Cable in every category. The company has a lot of work to do to improve scores in price / value and customer support, both of which remain very low for both technologies

Campbell's Company (The): La Regina acquisition is moderately leveragi...

Acquisition will delay deleveraging post Sovos but secures important supply chain

Novo Nordisk A/S - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

David Barden ... (+2)
  • David Barden
  • Vikash Harlalka

The future of broadband 3Q25: Our updated broadband industry forecast ...

In this report, our latest broadband outlook tome, in addition to forecasting the future of broadband by technology for the next 5 years, we undertake a sensitivity analysis for Cable's end-state market share possibilities. We also refresh our work on the relative competitive positioning of carriers based on end-user cNPS scores via our Recon Analytics partnership.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...

Novo Nordisk A/S: Key facts and statistics - LTM June 2025

A summary company profile, detailing Novo Nordisk A/S’s business operations and financial highlights.

Unilever PLC: Update to credit analysis

Our credit view of this issuer reflects its excellent product and geographic diversity and its strong brands, against its ever constant competitive pressures.

Eli Lilly & Co: 1 director

Two Directors at Eli Lilly & Co sold 306,000 shares at between 1,010.500USD and 1,011.184USD. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...

Merck & Co Inc: 1 director

A director at Merck & Co Inc sold 7,085 shares at 87.000USD and the significance rating of the trade was 94/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: November 7, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Conagra Brands Inc: 1 director

A director at Conagra Brands Inc sold 13,011 shares at 17.190USD and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

David Barden
  • David Barden

Autumn for Broadband 3Q25 – FWA ascendant, Cable struggling

We share here, in our latest Autumn for Broadband report, a quick update on broadband industry trends based on reported company results so far. Industry net adds have improved substantially from a year ago but remain below last year’s when adjusted for ACP impact. Net adds for the quarter were higher than the pre-pandemic norm but trailing twelve-month net adds remain below pre-pandemic levels. We take a deep-dive into FWA’s continued strong momentum by carrier.

Vikash Harlalka
  • Vikash Harlalka

CHTR: Lowering broadband and EBITDA estimates post 3Q

In this note, we cover changes to our estimates and how we compare to guidance and consensus. We also look at Charter’s relative valuation in comparison to Comcast. Please see our separate notes reviewing results and thoughts following the earnings call. We have lowered 4Q broadband new adds and ARPU. We have also lowered our total revenue and EBITDA expectations.

Vikash Harlalka
  • Vikash Harlalka

Charter: Subscribers and EBITDA growth heading lower

There is a lot that’s common between Charter and Comcast, and yet there is a lot that’s different about the two companies. Both are operating in an environment where broadband subscriber growth remains a distant dream. Where the two companies differ is expectation around EBITDA growth. While both companies expect EBITDA to decline in 4Q25, Charter expects to grow EBITDA in 2026 unlike Comcast which expects EBITDA to decline in 2026. We also think Charter has higher pricing power than Comcast.

Vikash Harlalka
  • Vikash Harlalka

CHTR 3Q25 Quick Take: Subs and EBITDA miss

Charter’s broadband losses were higher than expected. 3Q is usually a seasonally stronger quarter yet subscriber losses showed little sign of improvement vs. 2Q. EBITDA also missed estimates. On the call, we are keen to hear what’s driving the higher subscriber losses. We expect the stock to trade down, but, like CMCSA yesterday, where it winds up for the day will depend on commentary around expected 4Q subscriber and EBITDA trends.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch